Akinori Okumura1, Hiroyuki Unoki-Kubota1, Natsuyo Yoshida-Hata2, Ritsuko Yamamoto-Honda3, Shigeo Yamashita4, Minoru Iwata5, Kazuyuki Tobe5, Hiroshi Kajio3, Mitsuhiko Noda6, Naomichi Katai2, Satoshi Yamagoe7, Yasushi Kaburagi8. 1. Department of Diabetic Complications, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. 2. Department of Ophthalmology, Center Hospital, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. 3. Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. 4. Department of Diabetes and Endocrinology, JR Tokyo General Hospital, Tokyo 151-8528, Japan. 5. First Department of Internal Medicine, Faculty of Medicine, University of Toyama, Toyama 930-0194, Japan. 6. Department of Diabetes, Endocrinology, and Metabolism, Center Hospital, National Center for Global Health and Medicine, Tokyo 162-8655, Japan; Department of Endocrinology and Diabetes, Saitama Medical University, Saitama 350-0495, Japan. 7. Department of Chemotherapy and Mycosis, National Institute of Infectious Diseases, Tokyo 162-8640, Japan. 8. Department of Diabetic Complications, Diabetes Research Center, Research Institute, National Center for Global Health and Medicine, Tokyo 162-8655, Japan. Electronic address: kaburagi@ri.ncgm.go.jp.
Abstract
BACKGROUND: Vascular endothelial growth factor (VEGF) signaling is an important pathway in the development of diabetic retinopathy (DR). A recent report showed that leukocyte cell-derived chemotaxin 2 (LECT2) suppresses the VEGF signaling in endothelial cells. However, the clinical relevance of LECT2 in DR is unknown. This study aimed to investigate serum LECT2 levels and the presence of DR. METHODS: The study included 230 people with type 2 diabetes mellitus (DM), 95 with DR and 135 without DR. Serum LECT2 levels were measured using an enzyme-linked immunosorbent assay. Data were evaluated using Spearman's rank correlation, univariate and multivariate logistic regression. RESULTS: Serum LECT2 levels were significantly lower in participants with DM having DR than in those not having DR (35.6±14.9ng/ml vs. 44.5±17.6ng/ml, P<0.001). Spearman's rank correlation analysis revealed a significant association between serum LECT2 levels and the presence of DR (P<0.001). Multiple regression analysis revealed that serum LECT2 levels were independently related to DR (P<0.001). CONCLUSIONS: These findings indicated that serum LECT2 level is negatively associated with the presence of DR and suggest that low circulating LECT2 level is a risk factor for DR. Copyright Â
BACKGROUND:Vascular endothelial growth factor (VEGF) signaling is an important pathway in the development of diabetic retinopathy (DR). A recent report showed that leukocyte cell-derived chemotaxin 2 (LECT2) suppresses the VEGF signaling in endothelial cells. However, the clinical relevance of LECT2 in DR is unknown. This study aimed to investigate serum LECT2 levels and the presence of DR. METHODS: The study included 230 people with type 2 diabetes mellitus (DM), 95 with DR and 135 without DR. Serum LECT2 levels were measured using an enzyme-linked immunosorbent assay. Data were evaluated using Spearman's rank correlation, univariate and multivariate logistic regression. RESULTS: Serum LECT2 levels were significantly lower in participants with DM having DR than in those not having DR (35.6±14.9ng/ml vs. 44.5±17.6ng/ml, P<0.001). Spearman's rank correlation analysis revealed a significant association between serum LECT2 levels and the presence of DR (P<0.001). Multiple regression analysis revealed that serum LECT2 levels were independently related to DR (P<0.001). CONCLUSIONS: These findings indicated that serum LECT2 level is negatively associated with the presence of DR and suggest that low circulating LECT2 level is a risk factor for DR. Copyright Â
Authors: Jian-Bo Zhou; Jing Yuan; Xing-Yao Tang; Wei Zhao; Fu-Qiang Luo; Lu Bai; Bei Li; Jia Cong; Lu Qi; Jin-Kui Yang Journal: J Int Med Res Date: 2019-09-23 Impact factor: 1.671